Literature DB >> 16781827

Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma.

Tanja Batinac1, Gordana Zamolo, Miran Coklo, Ita Hadzisejdic, Christophe Stemberger, Gordana Zauhar.   

Abstract

Some authors view keratoacanthoma (KA) as a variant of squamous cell carcinoma (SCC), while others consider it a separate entity that must be distinguished from SCC. Involution displayed by KA is an important difference between these two entities. It has been suggested that apoptosis plays a role in the involution process of KA, although the exact trigger for it remains unclear. A hundred and fifty specimens were included in this study, 30 cases for each of the following groups: normal skin (NS), proliferative keratoacanthoma (pKA), regressing keratoacanthoma (rKA), well-differentiated squamous cell carcinoma (wdSCC), and poorly differentiated squamous cell carcinoma (pdSCC). They were immunohistochemically examined for the expression of p53, Ki-67, bak, and bcl-2. Significantly higher p53 and Ki-67 expressions were observed in all tumor lesions examined as compared with NS. There was higher bak expression in KAs compared to NS and a significant reduction of bak expression in pdSCC together with a significant reduction of bak expression in SCCs compared to pKA. Bcl-2 expression was similar in NS and SCCs, but was lower in rKA. We found a significant positive correlation between p53 and Ki-67, p53 and Bak in NS and examined skin tumors. Lower bcl-2 expression in conjunction with higher bak expression in rKA suggests a possible role of these apoptosis-regulating proteins in tumor regression. In contrast to this finding, a steady level of bcl-2 expression in pdSCC combined with lower bak expression levels and a high proliferation rate could contribute to progression and aggressiveness in these tumors. Bak and p53 expression is a sun-related and age-dependent process in NS and skin tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781827     DOI: 10.1016/j.prp.2006.04.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

1.  The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study.

Authors:  Recep Bedir; Hasan Güçer; İbrahim Şehitoğlu; Cüneyt Yurdakul; Pelin Bağcı; Pelin Üstüner
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

2.  RhoB promotes cancer initiation by protecting keratinocytes from UVB-induced apoptosis but limits tumor aggressiveness.

Authors:  Nicolas Meyer; Alexis Peyret-Lacombe; Bruno Canguilhem; Claire Médale-Giamarchi; Kenza Mamouni; Agnese Cristini; Sylvie Monferran; Laurence Lamant; Thomas Filleron; Anne Pradines; Olivier Sordet; Gilles Favre
Journal:  J Invest Dermatol       Date:  2013-06-21       Impact factor: 8.551

3.  Keratoacanthoma and squamous cell carcinoma are distinct from a molecular perspective.

Authors:  Seong H Ra; Albert Su; Xinmin Li; Jaime Zhou; Alistair J Cochran; Rajan P Kulkarni; Scott W Binder
Journal:  Mod Pathol       Date:  2015-02-13       Impact factor: 7.842

4.  IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.

Authors:  S Soddu; E Di Felice; S Cabras; M E Castellanos; L Atzori; G Faa; L Pilloni
Journal:  Eur J Histochem       Date:  2013-02-14       Impact factor: 3.188

5.  Clinical, histopathological and immunohistochemical study of keratoacanthoma.

Authors:  Alina Maria Vîlcea; Loredana Elena Stoica; Claudia Valentina Georgescu; Florina Carmen Popescu; Raluca Niculina Ciurea; Ionică Daniel Vîlcea; Cecil Sorin Mirea
Journal:  Rom J Morphol Embryol       Date:  2021 Apr-Jun       Impact factor: 1.033

6.  Immunohistochemical evaluation of p53 and Ki67 expression in skin epithelial tumors.

Authors:  Effat Khodaeiani; Ashraf Fakhrjou; Mehdi Amirnia; Shahla Babaei-Nezhad; Farshid Taghvamanesh; Elham Razzagh-Karimi; Hossein Alikhah
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.